EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

14 September 202114 September 2021

EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications has closed an oversubscribed USD $21.5 million (UK £15.5m) Series A financing round. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities. The company was founded by EBS alumni Dr James McIlroy after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies.

Supplant announces $24m investment

We’re delighted to learn that EBS alumni Dr Tom Simmons and his company Supplant Inc., have just closed a series-A venture capital financing round to commercialise their low-cost sugar replacement made from plant fibre. The company, started in 2017 after […]

EBS Alumni Dr Rotimi Alabi shares his experience of working with EBS

My entrepreneurship journey really got off to a start when I joined the RSE Enterprise Fellowship program which EBS delivered. This one year programme created the foundation that my knowledge of running and building a business is built on. The […]

£3.5m Seed Round for Cytoseek

Another EBS alumni to thrive following 12 months intensive training with EBS has been Dr Ben Carter. Ben is a founder and COO of Cytoseek Ltd., a spinout from University of Bristol, developing technology that will allow a whole new […]